Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 175Neoplasm Metastasis 19Breast Neoplasms 19Prostatic Neoplasms, Castration-Resistant 17Neoplasms 16Metastatic Castration Resistant Prostate Cancer 8Prostate Cancer Metastatic 7Metastatic Castration-Resistant Prostate Cancer 7Triple Negative Breast Neoplasms 6Metastatic Castration-resistant Prostate Cancer 6Parkinson Disease 4, Autosomal Dominant Lewy Body 5Pancreatic Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Melanoma 4Colorectal Neoplasms 4Castration-resistant Prostate Cancer 4Bulbo-Spinal Atrophy, X-Linked 4Adenocarcinoma 4Urinary Bladder Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Prostate Adenocarcinoma 3Ovarian Neoplasms 3Carcinoma, Hepatocellular 3mCRPC 2Uterine Cervical Neoplasms 2Recurrence 2Prostatic Diseases 2Metastatic Hormone Sensitive Prostate Cancer 2Metastatic Castration-Resistant Prostate Cancer (mCRPC) 2

Interventions

sipuleucel-T 2enzalutamide 2pamiparib 1gallium 68 PSMA-11 1fluzoparib 1Vancomycin 1Prednisone 1Metronidazole 1Docetaxel 1Ciprofloxacin 1Amoxicillin 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Metastatic Castration-Resistant Prostate Cancer (mCRPC) × enzalutamide × Clear all
NCT06126731 2025-11-24

Combination Study of Antibiotics With Enzalutamide (PROMIZE)

Institute of Cancer Research, United Kingdom

Phase 1/2 Recruiting
39 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT04015622 2025-08-20

PROTRACT

British Columbia Cancer Agency

Phase 2 Active not recruiting
100 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡